home

Breaking News

Redox Signs Licensing Agreement With OPKO Health, Inc.
On June 12, 2008, OPKO and Redox entered into an agreement whereby OPKO acquired the rights for all ophthalmic uses of Doxovir.

see OPKO Press Release

Redox Pharmaceutical Corporation has been granted approval from Health Canada to perform clinical studies on Herpes Labialis (cold sores).  Phase IB Clinical Trials (initial proof of safety and efficacy) have been successfully completed. A Phase II Clinical Trial on Herpes Labialis has been approved and has now been initiated.


©2008 Redox Pharmaceutical Corporation.
All right reserved.

Send us your site suggestions & service requests.

Site hosted by: Transbeam.com
Non-Steroidal Anti-Inflammatory
Non-Steroidal Anti-Inflammatory
Redox’s family of cobalt Schiff base chelates were initially designed and developed for their capacity to scavenge superoxide radicals. Our drugs possess anti-inflammatory properties by virtue of this property. This activity promotes and enhances recovery of virus-damaged tissues. Further studies are planned for exploring this application in various systems.
Contact Us | Home

MEDICAL APPLICATIONS

Ocular Applications Adenovirus-derived Keratoconjunctivitis Herpetic Keratitis

Genital Applications Overview
HIV
Human Papillomavirus
Genital Herpes
Chlamydia

Dermal Application
Facial Herpes

Anti-Inflammatory Application
Non-Steroidal anti-inflammatory